Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANRO 
Alto Neuroscience, Inc. (ANRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ANRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.33
1 Year Target Price $10.33
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.93% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 105.33M USD | Price to earnings Ratio - | 1Y Target Price 10.33 |
Price to earnings Ratio - | 1Y Target Price 10.33 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 1.60 - 15.04 | Updated Date 09/15/2025 |
52 Weeks Range 1.60 - 15.04 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.72% | Return on Equity (TTM) -42.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -14947914 | Price to Sales(TTM) - |
Enterprise Value -14947914 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 27076600 | Shares Floating 17884113 |
Shares Outstanding 27076600 | Shares Floating 17884113 | ||
Percent Insiders 7.48 | Percent Institutions 64.06 |
Upturn AI SWOT
Alto Neuroscience, Inc.
Company Overview
History and Background
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company dedicated to redefining psychiatry with precision neuropsychiatry. Founded in 2019, Alto uses its Precision Psychiatry Platform to develop targeted medicines for patients with mental health conditions. They aim to identify the right patients for the right treatments.
Core Business Areas
- Drug Development: Developing novel therapies for depression, PTSD, schizophrenia, and other mental health conditions. Focus on identifying biomarkers to improve clinical trial outcomes.
- Precision Psychiatry Platform: Utilizing brain biomarkers to identify likely responders to specific treatments, aiming to improve efficacy and reduce trial and error in mental health treatment.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates in specific patient populations. They have a pipeline of several drug candidates in various stages of clinical development.
Leadership and Structure
Dr. Amit Etkin is the founder and CEO. The company has a management team with experience in neuroscience, drug development, and clinical research. They have a board of directors with expertise in venture capital and pharmaceutical industry.
Top Products and Market Share
Key Offerings
- ALTO-100 (depression): A novel therapeutic targeting cognitive impairment in depression. Currently in clinical development. Market share is not yet applicable as the product is pre-revenue. Competitors include traditional antidepressants (SSRIs, SNRIs) and other emerging therapies for depression.
- ALTO-203 (PTSD): A novel therapeutic targeting specific neural circuits implicated in PTSD. Currently in clinical development. Market share is not yet applicable as the product is pre-revenue. Competitors include SSRIs/SNRIs, psychotherapy, and potentially other emerging therapies for PTSD.
- ALTO-300 (Schizophrenia): A novel therapeutic in development for Schizophrenia patients. Currently in clinical development. Market share is not yet applicable as the product is pre-revenue. Competitors include antipsychotic medication.
Market Dynamics
Industry Overview
The mental health therapeutics market is a large and growing market, driven by increasing prevalence of mental health disorders, increasing awareness, and growing demand for effective treatments. The market is competitive, with several large pharmaceutical companies and smaller biotech companies developing novel therapies.
Positioning
Alto Neuroscience is positioning itself as a leader in precision psychiatry, using brain biomarkers to develop targeted therapies and improve treatment outcomes. They are focusing on specific patient populations with unmet needs. They aim to differentiate themselves by using a data driven approach to drug development.
Total Addressable Market (TAM)
The global market for mental health therapeutics is estimated to be in the hundreds of billions of dollars. Alto Neuroscience is targeting specific segments of this market with its precision psychiatry approach. Exact TAM varies by indication and drug candidate but represents significant potential if their therapies are successful.
Upturn SWOT Analysis
Strengths
- Precision Psychiatry Platform
- Experienced Management Team
- Strong Intellectual Property
- Novel Drug Candidates
- Focus on unmet needs
Weaknesses
- Early Stage Company
- High R&D Costs
- Regulatory Risks
- Commercialization Risks
- Dependence on Clinical Trial Success
Opportunities
- Partnerships with Pharmaceutical Companies
- Expansion to New Indications
- Advancements in Biomarker Technology
- Increasing Awareness of Mental Health
- Growing Demand for Effective Treatments
Threats
- Competition from Established Pharmaceutical Companies
- Clinical Trial Failures
- Regulatory Hurdles
- Pricing Pressures
- Changes in Healthcare Policy
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- GSK
- SNY
- VRAY
- OGEN
Competitive Landscape
Alto Neuroscience competes with larger pharmaceutical companies developing treatments for mental health disorders. Their competitive advantage lies in their precision psychiatry approach, which aims to improve treatment outcomes by identifying the right patients for the right treatments. However, they face the challenges of being a smaller company with limited resources compared to their larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by progress in clinical trials, expansion of the pipeline, and successful fundraising rounds.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates. Analyst estimates are not readily available given the company's early stage, but projections would focus on potential market penetration and revenue generation upon product launch.
Recent Initiatives: Recent initiatives include advancing clinical trials for ALTO-100 and ALTO-203, expanding the Precision Psychiatry Platform, and forging partnerships with research institutions.
Summary
Alto Neuroscience is an early-stage biotech company pioneering precision psychiatry. Their strengths lie in their innovative platform and pipeline, but they face the inherent risks of drug development. Successful clinical trials and regulatory approvals are crucial for their growth. They need to carefully manage their cash burn and compete effectively with larger pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alto Neuroscience, Inc.
Exchange NYSE | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2024-02-02 | Founder, Chairman of the Board, CEO & President Dr. Amit Etkin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 76 | Website https://www.altoneuroscience.com |
Full time employees 76 | Website https://www.altoneuroscience.com | ||
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.